InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Share Price

Current share price for NUZ : $0.064 0.002 (3.23%)+

Neurizon Therapeutics Limited (NUZ) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is engaged in the development of its own drug discovery intellectual property for the treatment of neurological diseases.

NUZ General Information +

ASX Code NUZ
Website http://www.neurizon.com
Industry/Sector Pharmaceuticals
Market Cap ($M) 50
NUZ Share Price $0.064
Day High $0.065
Day Low $0.058
Last Close $0.062
NUZ Share Price Movement $0.00 ( 3.23% )
Prices as at 16:40, 6 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Neurizon Therapeutics Limited (NUZ) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Neurizon Therapeutics Limited (NUZ) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Neurizon Therapeutics Limited (NUZ) price-sensitive announcements

NUZ - Redemption of all remaining Obsidian convertible notes
Neurizon Therapeutics Limited (ASX: NUZ) announced on 2 November 2026 that it had redeemed
Neurizon Therapeutics Limited (NUZ)
2 Nov 2026 | 9:38 AM
NUZ - Firm commitments to raise A$4.3m and announcement of SPP
Neurizon Therapeutics Limited (ASX: NUZ) announced firm commitments to raise A$4.3 million
Neurizon Therapeutics Limited (NUZ)
2 Nov 2026 | 9:32 AM
NUZ - Trading Halt
ASX announced that trading in Neurizon Therapeutics Limited (ASX: NUZ) securities was plac
Neurizon Therapeutics Limited (NUZ)
29 Oct 2026 | 9:21 AM
NUZ - Appendix 4C & Quarterly Update
Neurizon Therapeutics Limited’s Quarterly Report and Appendix 4C for Q1 FY2027, released o
Neurizon Therapeutics Limited (NUZ)
28 Oct 2026 | 9:36 AM

Neurizon Therapeutics Limited (NUZ) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $51 Application for quotation of securities - NUZ 6 Nov 2026 10:56AM $0.059 $0.064 risen by 8.47%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $51 Investor webinar reminder and presentation 5 Nov 2026 9:58AM $0.065 $0.064 fallen by 1.54%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $51 Notification of cessation of securities - NUZ 2 Nov 2026 9:55AM $0.086 $0.064 fallen by 25.58%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $51 Withdrawal of Resolution 4 from Notice of AGM 2 Nov 2026 9:42AM $0.086 $0.064 fallen by 25.58%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $51 Redemption of all remaining Obsidian convertible notes 2 Nov 2026 9:38AM $0.086 $0.064 fallen by 25.58%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $51 Proposed issue of securities - NUZ 2 Nov 2026 9:33AM $0.086 $0.064 fallen by 25.58%

NUZ Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$10.72 -$1.80 -47.50% 0.00 0.00 0.00% 0.0%
2025A -$16.59 -$3.40 117.50% 0.00 0.00 0.00% 0.0%
2024A -$5.79 -$1.50 54.00% 0.00 0.00 0.00% 0.0%

NUZ Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Clarity Pharmaceuticals Ltd (CU6) $597M 0.4454 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,946M -0.7857 0.2462 0.9655 99.8711 80.1379 40.7719 0.00% 1.42% 1.68%
Neurizon Therapeutics Limited (NUZ) $49M -0.4746 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

NUZ Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 3.83 0.00
Market 0.30 13.40 1.03 0.75
Sector 0.78 33.40 2.19 2.23

NUZ Directors

Name Position Start Date
Mr Sergio Duchini Non-Executive Chairman, Non-Executive Director 17 May 2024
Dr Ross Murdoch Non-Executive Director 8 May 2026
Dr Kathryn(Katie) MacFarlane Non-Executive Director 17 Jun 2024
Mr Marcus Hughes Non-Executive Director 9 May 2024

Neurizon Therapeutics Limited (NUZ) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
14 Sep 2026 DUCHINI, Sergio Buy Direct Shares 372,960 $1.000 $372,960.000
30 Jun 2026 HUGHES, Marcus Buy Direct Shares 46,822 $0.058 $2,715.680
29 Jun 2026 HUGHES, Marcus Buy Direct Shares 3,340 $0.058 $193.720

See all changes in directors' interest & trades for Neurizon Therapeutics Limited (NUZ) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NUZ Management

Name Position
Daniel O'Connell CFO
Chris Bremer Chief Executive Officer
Stefan Ross Company Secretary

NUZ Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
39,000,000 (6.34%) Chek Loon Tan

NUZ Calendar of Events

Date Event
24 August 2027 Report (Annual)
24 August 2027 Report (Prelim)
24 February 2027 Report (Interim)
10 November 2026 AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.